Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
Using genotyping and tissue-specific expression data from the Genotype-Tissue Expression project, researchers characterized Neanderthal allele-specific expression.
